Τίτλος:
CCR2-64I and CXCL12 3′A alleles confer a favorable prognosis to AIDS patients undergoing HAART therapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: The chemokine receptor polymorphisms CCR5Δ32, CXCL12 3′A, CCR2-64I and CCR5-59029 G/A have been demonstrated to affect HIV-1 infection and progression. Objective: We studied the impact of the above polymorphisms on the effectiveness of a 30-month treatment with highly active antiretroviral therapy (HAART) in 149 HIV-1 patients. Study design: We stratified the patients according to CD4 CDC criteria and applied Kaplan-Meier analysis using the following end-point criteria: (a) the time from HAART initiation to undetectable viral load (VL) counts (VL < 50 copies/ml), (b) the duration of undetectable VL status and (c) the time required for CD4+ T-cell counts to pass over the 500 cells/ml threshold. Results: Our results in the second group (CD4 201-500) revealed that patients with the CCR2-64I allele achieved undetectable VL counts at 3.5 ± 0.48 months as compared to 10.26 ± 1.42 months in the control group (p = 0.018). The VL remained undetectable for 28 ± 2 months, in contrast to 20 ± 2 months in the control group (p = 0.048). Patients carrying CXCL12 3′A restored the CD4 population faster than the control group (9 ± 2 and 14 ± 2 months, respectively, p = 0.023). The CCR5Δ32 and CCR5-59029 G/A alleles did not appear to affect the parameters studied. Conclusions: Our results suggest that patients carrying either CCR2-64I or CXCL12 3′A have a more favorable prognosis during HAART treatment. © 2005 Elsevier B.V. All rights reserved.
Συγγραφείς:
Passam, A.M.
Zafiropoulos, A.
Miyakis, S.
Zagoreos, I.
Stavrianeas, N.G.
Krambovitis, E.
Spandidos, D.A.
Περιοδικό:
Journal of Clinical Virology
Λέξεις-κλειδιά:
antiretrovirus agent; RNA directed DNA polymerase inhibitor, acquired immune deficiency syndrome; adult; aged; allele; article; cell count; cell population; clinical trial; controlled clinical trial; controlled study; female; genetic polymorphism; highly active antiretroviral therapy; human; Human immunodeficiency virus infection; Kaplan Meier method; major clinical study; male; priority journal; prognosis; T lymphocyte; virus load, Acquired Immunodeficiency Syndrome; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemokines, CXC; HIV-1; Humans; Prognosis; Receptors, Chemokine
DOI:
10.1016/j.jcv.2004.05.021
